SynteractHCR

SynteractHCR moves headquarters to Carlsbad, California

Friday, October 6, 2017

SynteractHCR, a full-service global CRO, has recently moved to its expansive new facility in Carlsbad, California. The approximately 38,000 square feet of space at 5909 Sea Otter Place has been designed with an open concept to foster collaboration and creates a dynamic team environment, right in line with the company’s innovative business philosophy. Headquartered in San Diego County, with additional offices in the Research Triangle Park (RTP) area of North Carolina as well as 10 additional offices in Western, Central, and Eastern Europe, SynteractHCR sits in six of the top 10 biotech centers in the world and supports clients in conducting clinical trials worldwide.

[Read More]

Steve Powell named SynteractHCR CEO

Monday, July 17, 2017

SynteractHCR announced that Steve Powell has been appointed chief executive officer. Powell succeeds Wendel Barr, who departs SynteractHCR after six years as CEO. A portfolio company of Amulet Capital Partners, LP, SynteractHCR is a leading, international CRO focused on phase I-IV clinical trials for innovative biopharma clients in the U.S., Europe and Asia.

[Read More]

SynteractHCR, The GOG Foundation partner

Wednesday, June 7, 2017

SynteractHCR, a full-service, international CRO, and The GOG Foundation, a nonprofit focused on gynecologic oncology research, have signed a Teaming Agreement to work together on gynecologic oncology clinical studies. The relationship will offer a streamlined process for drug development companies to improve the timeliness of determining clinical research studies as well as facilitate high quality, rapid trial execution. The relationship is reciprocal and has a three-year term.

[Read More]

SynteractHCR adds three senior executives to management team

Thursday, April 20, 2017

SynteractHCR, a full-service, international CRO, has appointed three new senior-level managers to its leadership team to ensure internationally-cohesive, enhanced support for sponsors. SynteractHCR’s newest senior executives include: Heather Davis, executive director of U.S. Project Management; Zia Haque, executive director, Clinical Data Management, and John Whitaker, Ph.D. as executive director, Biostatistics. All will report to Marlo M. Vasquez, vice president, U.S. Operations at SynteractHCR.

[Read More]

SynteractHCR hires three to international leadership team

Wednesday, October 12, 2016

SynteractHCR, a full-service, international CRO, has appointed three new senior-level managers to strengthen its leadership team internationally. The new hires include Linda Rawlings as executive director strategic development, Pascale Goujard-Paquette as senior director of clinical operations in the EU, and Erin Parker as senior director of global medical operations. These three professionals have had extensive experience in clinical research delivery at a local, international and global level, and across a myriad of therapeutic areas.

[Read More]

IPOs in the CRO market remain steady

Monday, April 18, 2016

InVentiv Health has filed paperwork for an initial public offering (IPO) worth up to $100 million, following in the footsteps of three other large private equity-backed CROs that have gone public in recent years. Analysts see strong financial activity on the horizon for the CRO industry.

[Read More]